Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multi-center, Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure

NCT03063697 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.

NCT NCT03063697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03063697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multi-center, Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure
Lead sponsor
Chong Kun Dang Pharmaceutical
Phase
Observational
Overall status
Unknown status
Start date
November 30, 2015
Completion date
December 31, 2020
Enrollment
20,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic stable angina, congestive heart failure, essential hypertension